

To expedite processing, please send the following information with prescription.

Referral Form	List of Tried and Failed Mec (Including other Biologics)								
Demographic Sheet	Prescription Insurance Card (Front & Back)								
Most Recent Clinical Notes									
Bio-Coordinator or Primary Point of Contact at Clinic:									
Name:									
Email:									

Direct Phone Line: _____

Cell (optional, but preferred): -	

Genefic Specialty Pharmacy 2577 Mall Road, Suite B Florence, AL, 35630

> Phone: (833) 928-7660 Fax: (833) 928-7661 Website: GeneficRx.com

Faxed prescriptions will only be accepted from a prescriber. Patients must bring an original prescription to the pharmacy, and cannot fax these referral forms to Genefic Specialty Pharmacy.

Pediatric				Prescriber:				NPI:			
			Supervi	Supervising Physician:				NPI:			
Atopic Dermatitis			Address	Address:			Ta	Tax ID:			
Enrollment Form			Phone:			Fax:					
	Contact:										
Name:					PATIENT INFORMATION				SS#:		
			<u> </u>	Irans M L			<u>//</u>				
Street:			City:			State:		ZIP:			
Phone:	Alt	. Phone:			English	Spanish Othe	er:	Wt.:	Ht.:		
PRESCRIPTION											
	t received a loading dose/st	arter kit?	Yes Start D	ate:/_				Docto	's Office Other:	Defille	
Drug			ITIAL : Inject 300) ma (two 15	0 ma injection	Directions & Quant s) SQ at day 1 (Quant				Refills	
Adbry®	□ 150 mg Pre-filled Syring					ner week starting at da					
	□ 100 mg Tablet* □ Take 100 mg PO once d										
Cibinqo™	200 mg Tablet*					ntended for patients who ha	ve not achieved adequat	e respon	se with 100 mg daily dose***		
						EIGHT REQUIRED***					
			ect 300 mg SQ e						atients age 6 months to 5 years 5 kg/33 lbs to <30 kg/66 lbs***		
			ITIAL: Inject 600]	
	□ 300 mg Pre-filled Syring □ 300 mg Pen*	- IVI		Inject 300 mg	g SQ every 4	weeks starting at day	29 <u>old</u>	weight 1	atients age 6 years to 17 years 5 kg/33 lbs to <30 kg/66 lbs***		
			Quantity: 2)		av 1 (Quantity						
Dupixent®						· ∠) 1er week starting at da	av 15 ***Inten	ded for <u>p</u>	atients age 6 years to 17 years		
		(0	Quantity: 2)						r weight ≥ 60 kg/132 lbs***		
		D Inj	ect 200 mg SQ e	very 4 weeks	(Quantity: 2)		***Intended fo weigh	or <u>patient</u> nt 5 kg/11	is age 6 months to 5 years old lbs to <15 kg/33 lbs***		
	□ 200 mg Pre-filled Syring □ 200 mg Pen*	^е 🛛 IN	INITIAL: Inject 400 mg SQ at day 1 (Quantity: 2) ***Intended for patients age 6 years to 17 years]	
		Пм	AINTENANCE: Ir	nject 200 mg \$	Q every other	week starting at day 15	5 (Quantity: 2)		ended for weight 66 lbs to < 60 kg/132		
	2% Ointment 60 gm*										
Eucrisa®	2% Ointment 100 gm*		oply a thin layer t	to affected ar	ea(s) twice a	day (Quantity: 1 tube)					
Opzelura™	□ 1.5 % Cream 60 gm*		anly a thin layor t	to offected a		day (Quantity: 1 tube)					
Opzeiura			piy a unin layer i			EIGHT REQUIRED***	:				
Rinvog®	□ 15 mg Tablet*		ake 15 mg PO or	nce dailv (Qu				or patients age 12 years and older weighing ≥ 40 kg/88 lbs***			
	□ 30 mg Tablet*		Take 30 mg PO once daily (Quantity: 30) ***Intended for patients age 12 years and older weighing ≥ 40 kg/88 lbs if adequate response was not achieved with 15 mg daily dose***					older weighing ≥ 40 kg/88 lbs if 15 mg daily dose***			
*Adbry/Dupixent pens/Cibinqo/Opzelura/Rinvoq FDA approved for ages 12 and over *Eucrisa FDA approved for ages 3 months and over											
***	PLEASE FAX COPY OF PRE	COIDT						DECA			
PREVIOUS TH				Not Tolera		Contraindication:		REGA			
Hethotrexate	·)					(and white		
Cyclosporine											
Tacrolimus											
L Elidel	□ ()								
Protopic	□ ()								
□	D ()						Affected Areas		
<u> </u>	D ()						Groin Hand	ds	
PHOTOTHERAPY Tried & Failed (Duration): Not Tolerated: Contraindication: Image: Nails Scalp Other: Image: UVA /UVB Image: Output (Duration): Image: Output (Duration): Image: Output (Duration): Image: Output (Duration): Scalp Other: Image: Output (Duration): Image: Output (Duration): Image: Output (Duration): Image: Output (Duration): Scalp Other: Image: Output (Duration): Image: Output (Duration): Image: Output (Duration): Image: Output (Duration): Scalp Other: Image: Output (Duration): Image: Output (Du											
UVA /UVB Image: Constraint of the second							м				
L20.9 Atopic Dermatitis I (Mild to Moderate) (Moderate to Severe)											
Other: Date of Diagnosis:// Allergies:/											
Active TB is ruled out: UYes No Date: / / Hep B ruled out/treated: UYes No Date: / /											
	ical Information:								·/		
	INJECTION TRAINING										
	Patient has received pen an	d injectior	n training	Physician's	office to provid	le injection training	Genefic to c	oordina	ate injection training		
PRESCRIBER SIGNATURE <u>To Prescriber</u> : By signing this form and utilizing our services, you are also authorizing Genefic Specialty Pharmacy to serve as your prior authorization designated agent in dealing with medical and											
	prescription insurance companies, and co-pay assistance foundations.										
CONFIDENTIALITY NOTICE											
IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you											
should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.											